Sydney 2021 Virtual Meeting

The annual Population Approach Group in Australia and New Zealand (PAGANZ) meeting will be the first virtual PAGANZ meeting hosted in Sydney, Australia by the school of Pharmacy, University of Sydney; St Vincent’s Hospital, Sydney and St Vincent’s Clinical School, UNSW from Wednesday 27th January to Friday 29th January 2021.

Who should attend?

The PAGANZ meeting is the Australasian forum for scientists with a research and professional interest in the use of the population approach in pharmacokinetics and pharmacodynamics. A strong focus of this meeting is the application of population modelling and simulation techniques in the experimental, clinical and regulatory settings of drug development.

This meeting is designed for scientists and clinicians working in basic or clinical pharmacology research, pharmaceutical industry, regulatory bodies, and postgraduate students. The meeting combines a workshop given by leaders in the field and a scientific meeting giving researchers the opportunity to present and discuss their own work. This is an informal meeting and in the past has been very productive in helping and guiding researchers in this important area of pharmacology and drug development.


Wednesday 27th January to Friday 29th January 2021 (Sydney, Australia time (AEST)).

To register for the conference you must first register as a user of the PAGANZ website (the “Join the Society” link above). Once  this has been accepted, then you register for the meeting using the Registration link on the right-hand menu under the Sydney 2021 Virtual Meeting heading.

The cost of registration is AU$20.

Please note that you can use a credit card to register through the PayPal portal, and do not need a PayPal account.

Registration has closed.

Once you have registered you will receive an email confirming your registration. This email will also contain links which will enable you to select which PAWS and sessions you wish to attend.

Preconference Work Shops

The Population Analysis Work Shop (PAWS) courses will consist of lectures and demonstrations. After the demonstrations, tutors will be available for consultation and assistance. The Beginners Course for NONMEM and the Intermediate Course will be conducted as parallel sessions. Attendance at the Intermediate Course requires experience with the conduct of at least one population approach analysis.

The beginners course will introduce the theory and practice of population modelling with a demonstration session with NONMEM.

The intermediate course will provide an introduction to Time to Event analysis with a demonstration and Q&A session.

PAGANZ Scientific Meeting

The PAGANZ meeting will include a symposium highlighting progress in the application of the population approach to pharmacokinetics and pharmacodynamics since the first PAGANZ meeting 20 years ago. The symposium speakers include international and local experts in the field and presents a unique opportunity for Australasian scientists to see the best in action. Sessions will be dedicated to free communications and discussions providing a forum for researchers to present both completed work and work in progress and receive feedback and advice from their peers in an informal setting. The preliminary 2021 PAGANZ Scientific Program is available here. The program will be finalised once the abstract deadline has been met.

All sessions in the scientific program will be recorded, so you can listen to them at a time convenient to you.

PAGANZ Scientific Program Highlights

The scientific program is based on a combination of invited speakers and submitted abstracts.

We can confirm the following invited speakers:

Opening ISoP keynote speaker: Dr. Rada Savic

Dr. Rada Savic is a Professor at the Department of Bioengineering and Therapeutic Sciences and Division of Pulmonary and Critical Care Medicine at the University of California San Francisco, where she leads her Global Health Data and Modeling Team. Her expertise is in data science, data integration across multiple scales and advanced pharmacokinetic, biomarker, and pharmacodynamics modeling focused on optimizing drug development process and improving outcomes in all patients, including children and pregnant women.  Dr. Savic is scientific leader on several Global Health large-data initiatives directed by Center for Disease Control, Bill and Melinda Gates Foundation, and World Health Organization. She trained in clinical pharmacology, biostatistics, pharmacy, and pharmacometrics at institutions in Sweden, France, Serbia, and US.

Pharmacometrics in SARS-CoV-2 session speakers

Dr Mike Dodds is executive director of Integrated Drug Development at Certara.  Mike’s research focuses on the application of pharmacometrics: mathematical models of biology, (patho)-physiology, pharmacology and disease that quantify beneficial and undesirable interactions between drugs and patients to predict outcome [Barrett 2008]. Importantly, accurate and precise quantitative prediction of patient outcome allows for informed drug-development decisions. The following sections detail examples where Mike has applied pharmacometric research principals to aid in drug-development, with an emphasis on decision quality and business impact.

Antonio Gonçalves is a 3rd year PhD student in the INSERM research team ‘Biostatistical Modelling and Pharmacometrics in treatment of Infectious Diseases’ headed by France Mentré. Pharmacist by training, Antonio has also Master’s degrees in both Pharmacometrics and Biostatistics and prospects a position of pharmacometrician in the pharmaceutical industry. As a PhD student, he works on the development of viral dynamic models of acute and chronic infections (Hepatitis B, SARS-CoV-2) to gain knowledge on the disease and improve drug development.